Mobile

A prospective single centre, open label, pilot study to evaluate the safety of ICXP007 plus standard of care, for the treatment of lower extremity chronic, neuropathic diabetic foot ulcers

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-000692-15

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary safety objective is to determine the safety of ICXP007 plus standard of care in the treatment of chronic diabetic foot ulcers. The primary efficacy objective is to determine the efficacy of ICXP007 plus standard of care in achieving complete ulcer closure at 12 weeks in chronic, neuropathic diabetic foot ulcers of greater than four weeks duration.

Critère d'inclusion

  • DIABETIC FOOT ULCERS

Liens